[1] |
李勇,黄露萍,晏坤,等. 某院耐碳青霉烯类肠杆菌科细菌的分布及耐药性分析[J]. 临床输血与检验,2018,20(1):57-60.
|
[2] |
支晓阳,林雪峰. 某地区耐碳青霉烯类抗菌药物肠杆菌科细菌的临床感染状况及耐药性分析[J]. 中国卫生检验杂志,2018,28(9):1063-1066.
|
[3] |
周庭银,倪语星,胡继红,等. 临床微生物检验标准化操作[M]. 3版. 上海:上海科学技术出版社,2015:53-497.
|
[4] |
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S28,CLSI,2018.
|
[5] |
刘雅,康梅. 临床分离的耐碳青霉烯类肠杆菌科细菌的研究进展[J]. 华西医学,2013,28(4):631-636.
|
[6] |
储雯雯,刘周,杨凯,等. 碳青霉烯耐药肺炎克雷伯菌耐药机制及分子流行病学研究[J]. 安徽医科大学学报,2016,51(6):809-812.
|
[7] |
ZUCKERMAN T,BENYAMINI N,SPRECHER H,et al.SCT in patients with carbapenem resistant Klebsiella pneumoniae:a single center experience with oral gentamicin for the eradication of carrier state[J]. Bone Marrow Transplant,2011,46(9):1226-1230.
|
[8] |
LANDMAN D,BABU E,SHAH N,et al.Transmission of carbapenem-resistant pathogens in New York City hospitals:progress and frustration[J]. J Antimicrob Chemother,2012,67(6):1427-1431.
|
[9] |
胡付品,朱德妹,汪复,等. 2012年中国CHINET碳青霉烯类耐药肠杆菌科细菌的分布特点和耐药性分析[J]. 中国感染与化疗杂志,2014,14(5):382-386.
|
[10] |
HU F P,GUO Y,ZHU D M,et al.Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance,2005-2014[J]. Clin Microbiol Infect,2016,22(Suppl 1):S9-S14.
|
[11] |
张敬霞,贾天野,张树永,等. 头孢他啶/阿维巴坦对耐碳青霉烯肠杆菌科细菌的体外抗菌活性研究[J]. 中国抗生素杂志,2018,43(9):1109-1116.
|
[12] |
WINKLER M L,PAPP-WALLACE K M,TARACILA M A,et al. Avibactam and inhibitor-resistant SHV β-lactamases[J]. Antimicrob Agents Chemother,2015,59(7):3700-3709.
|
[13] |
许红霞,杨少辉,邢健昆. 新型抗菌药物头孢他啶/阿维巴坦的研究进展[J]. 西北药学杂志,2018,33(4):567-568.
|
[14] |
卞聪,马贝贝,胡来兴,等. 金属碳青霉烯酶的作用机制及其抑制剂研究进展[J]. 中国抗生素杂志,2017,42(11):923-931.
|